Unique Place Among Biotechnology News
- FONTERRA'S NEW CEO Wednesday, July 13, 2011 @ 8:33PMFonterra Co-operative, a global leader in dairy nutrition today announced the appointment of Mr Theo Spierings as its new CEO.
- Kane Biotech Submits DispersinB(R) Wound Spray Briefing Document to the FDA Thursday, July 7, 2011 @ 8:05AMWINNIPEG, MANITOBA --(Marketwire - July 7, 2011) - Kane Biotech Inc. (TSX VENTURE:KNE), a biotechnology company engaged in the development and commercialization of products that prevent and remove microbial biofilms is pleased to announce that it has submitted its Briefing Document on DispersinB ® wound spray, to the United States Food and Drug Administration (FDA) for review and comments. This ...
- Brazil, Portugal and Czech Republic Among Growing Bio-Innovation Players Wednesday, June 29, 2011 @ 3:47PMWASHINGTON--(BUSINESS WIRE)--Brazil, Portugal and Czech Republic Among Growing Bio-Innovation Players
- Global Hunger, Diabetes and Innovations from Emerging Regions Headline Third Day of 2011 BIO International Convention Wednesday, June 29, 2011 @ 6:15AMWASHINGTON--(BUSINESS WIRE)--The third day of the 2011 BIO International Convention focuses on food and agriculture biotechnology advancements and the promise of sector growth throughout emerging regions.
- Two Delaware Students Advanced to International BioGENEius Challenge in Washington, D.C. Tuesday, June 28, 2011 @ 7:28PMStudents recognized for exemplary understanding of biotechnology through science research projects. (PRWeb June 28, 2011) Read the full story at http://www.prweb.com/releases/2011/6/prweb8608678.htm
- PolyMedix Presents Data Showing Antimicrobial Activity of Sutures Containing PolyCide Tuesday, June 28, 2011 @ 6:16AMRADNOR, Pa.--(BUSINESS WIRE)--PolyMedix, Inc. (OTC BB: PYMX), an emerging biotechnology company focused on developing new therapeutic drugs to treat life-threatening infectious diseases and acute cardiovascular disorders, presented data showing that its PolyCide® materials are active as agents for use in antimicrobial sutures. PolyCides are synthetic antimicrobial compounds that mimic the ...
- Health and fitness agenda: BIO International and pHealth Friday, June 24, 2011 @ 10:50AMComing up, thousands of biotech professionals will gather in Washington, DC, to discuss new technologies and trends, while nanotech researchers zero in on emerging health technologies at pHealth in Lyon.
- Education briefs for June 23 Thursday, June 23, 2011 @ 10:40AMStarting in the fall 2011 semester, Capitol College will begin offering a 10 percent discount on all its master’s degree programs to new alumni applicants.
- Poniard Pharmaceuticals and ALLOZYNE Sign Definitive Merger Agreement Wednesday, June 22, 2011 @ 3:54PMCombined Company to Focus on Advancing ALLOZYNE's Clinical Stage Product Pipeline and Next Generation Biologics Platform; Will Seek Partnership for Picoplatin Conference Call Scheduled for Today, June 22, at 5:00 PM Eastern Time
- 13therapeutics Is Selected to Present at 2011 BIO International Convention. Wednesday, June 22, 2011 @ 8:00AM13therapeutics, Inc. has been selected to present at the 2011 BIO International Convention which takes place in Washington DC June 27-30 at the Walter E.
- CORRECTING and REPLACING 47th Annual DIA Meeting Exhibitor Profiles J through Z Monday, June 20, 2011 @ 12:04PMIn release dated June 17, 2011, please note that the NeuroVive Pharmaceutical profile was inadvertently included and has been removed.
- Concert Pharmaceuticals Announces Advancement of Novel Drug Candidates in Kidney Disease and Spasticity Monday, June 20, 2011 @ 7:05AMConcert Pharmaceuticals, Inc. announced today the advancement of two programs from its DCE PlatformT (deuterated chemical entity platform). CTP-499 is progressing into Phase 2 clinical trials for diabetic nephropathy and C-21191 has been selected as a lead candidate for spasticity.
- 47th Annual DIA Meeting Exhibitor Profiles J through Z Friday, June 17, 2011 @ 3:08PMThe Drug Information Association’s 47th Annual Meeting takes place June 19, 2011 through June 23, 2011 at McCormick Place in Chicago. Listed below are exhibitor profiles J through Z.
- Health and fitness agenda: Mind Over Madness Yoga in NYC Thursday, June 16, 2011 @ 1:37PMComing up, yogis in New York will unroll their mats in Times Square for a day of free yoga classes. Later this month: the BIO International Convention in Washington, DC.
- Dendreon CEO Dr. Mitchell Gold Named Ernst & Young Entrepreneur Of The Year® 2011 Pacific Northwest Award Winner Monday, June 13, 2011 @ 9:23PMSEATTLE, June 13, 2011 /PRNewswire/ -- Dendreon Corporation (Nasdaq: DNDN) today announced that Mitchell H. Gold, M.D., President and Chief Executive Officer received the Ernst & Young Entrepreneur Of The Year (®) 2011 Pacific Northwest Award in the Emerging Sciences category. Dr. Gold has served as CEO of Dendreon since 2003, and under his leadership the company last year received U.S. Food and ...
- One-Year Follow-Up Results From Athersys' Phase I Study of MultiStem in Heart Attack Patients Presented at ... Monday, June 13, 2011 @ 6:00AMCLEVELAND -- Athersys, Inc. announced positive results from the analysis of one-year follow-up data from its Phase I clinical trial of MultiStem, its allogeneic adult stem cell product, administered to individuals following acute myocardial infarction , more commonly referred to as a heart attack.
- Memphis Can Learn From Canada’s Bio Model Wednesday, June 8, 2011 @ 4:21PMThe typical driver probably isn’t aware of how much soy product their car contains. From the color of the seats to the foam in the dashboard to ...
- Hydrogen Storage Collaboration Between Sigma-Aldrich and Ilika Technologies to Scale-up and Commercialize Boron ... Tuesday, June 7, 2011 @ 9:00AMAldrich Materials Science, a strategic technology initiative of Sigma-Aldrich Corporation today announced it has signed an agreement to collaborate on the scale-up and commercialization of next generation hydrogen-storage materials with Ilika plc , an advanced cleantech materials discovery company.
- Pharma and Biotech CEOs, Academic Scientists, Funders and Patients to Meet on ALS Drug Development this Fall Monday, June 6, 2011 @ 7:00AMCAMBRIDGE, Mass., June 6, 2011 /PRNewswire-USNewswire/ -- The ALS Therapy Development Institute (ALS TDI) announced today the agenda for its 7th annual Leadership Summit to be held in Cambridge on November 4th, 2011. This year's Leadership Panel will feature: Christopher Austin, Ph.D., scientific director of the National Institutes of Health Center for Translational Therapeutics; Robert Blum ...
- Wake Forest Baptist Medical Center and Cornerstone Pharmaceuticals Present Interim Data From Phase I Trial of CPI-613 ... Friday, June 3, 2011 @ 11:11AMCHICAGO, June 3, 2011 /PRNewswire/ -- Cornerstone Pharmaceuticals and Wake Forest Baptist Medical Center today announced key findings from a Phase I clinical trial of Cornerstone's first-in-class cancer metabolism inhibitor drug, CPI-613 in Acute Myeloid Leukemia (AML). Data will be presented at the 47th Annual meeting of American Society of Clinical Oncology (ASCO): http://www ...
- ZYTIGA clinical study data on prostate cancer to be presented at ASCO 2011 Friday, June 3, 2011 @ 7:14AMData related to ZYTIGA (abiraterone acetate) will be presented at the 2011 American Society of Clinical Oncology (ASCO) Annual Meeting in Chicago.
- Venrock Extends Leading Healthcare IT Franchise, Adds Robert Kocher Friday, May 27, 2011 @ 7:15AMFormer White House Advisor Will Focus on Healthcare Innovation
- Cowen Seeing Weak Growth Makes ‘Great Stagnation’ Hotly Debated Bestseller Thursday, May 26, 2011 @ 5:13PMTyler Cowen sits with a cranberry juice and a pile of books he no longer intends to read. He’s at Harry’s Tap Room, near the Air France ticket counter in the main terminal of Dulles International Airport, on his way to São Paulo.
- PolyMedix Presents Antimicrobial Compound Data at Two Prestigious Scientific Meetings Wednesday, May 25, 2011 @ 6:11AMRADNOR, Pa.--(BUSINESS WIRE)--New pre-clinical data for PolyMedix's novel, defensin-mimetic antimicrobial compounds was recently presented at two prestigious scientific meetings, including the American Society of Microbiology.
- Athersys Announces Positive Interim Results From Ongoing Phase I Study of MultiStem(R) for Hematopoietic Stem Cell ... Wednesday, May 25, 2011 @ 6:00AMCLEVELAND -- Athersys, Inc. today announced positive interim results from an ongoing Phase I clinical trial of MultiStem, its cell therapy product, administered to individuals undergoing allogeneic hematopoietic stem cell transplants for the treatment of leukemia and related conditions.
- Novo Energies Corp. Enters Into a Memorandum of Understanding to Acquire Biotech Firm Immunovative Clinical Research ... Thursday, May 19, 2011 @ 7:36AMNEW YORK, NY--(Marketwire - May 19, 2011) - Novo Energies Corp. ( OTCBB : NVNC ) has today announced that it has entered into a Memorandum of Understanding ("MOU") to acquire Immunovative Clinical Research Inc. ("ICRI"), a wholly-owned subsidiary of world-class, Israel-based biotechnology firm Immunovative Therapies, Ltd. ("Immunovative").
- Meet the Class of 2011: An Overview of Rensselaer's 205th Commencement Thursday, May 19, 2011 @ 7:24AMThis year, 1,700 students will receive degrees from Rensselaer Polytechnic Institute on Saturday, May 28, beginning at 9:30 a.m. in the East Campus Athletic Village (ECAV) stadium. They represent the next generation of leaders, engineers, scientists, entrepreneurs, patent holders, game designers, and innovators, in fields ranging from engineering to architecture, from fine arts to science, from ...
- PolyMedix PMX-30063 Defensin-Mimetic Antibiotic Compound Shows Promising Activity for Oral Mucositis Thursday, May 19, 2011 @ 6:14AMRADNOR, Pa.--(BUSINESS WIRE)--PolyMedix, Inc. (OTC BB: PYMX), a biotechnology company focused on developing new therapeutic drugs to treat patients with acute infectious diseases and cardiovascular disorders, announced today that its lead defensin-mimetic antibiotic compound, PMX-30063, when administered topically as an oral rinse, has shown activity against oral mucositis in an animal study ...
- Exelixis Launches Online Summit Featuring Expert Perspectives on Cancer Treatment Advances and ASCO Highlights Wednesday, May 18, 2011 @ 5:14AMSOUTH SAN FRANCISCO, Calif.--(BUSINESS WIRE)--Exelixis, Inc. (Nasdaq:EXEL) announced today the launch of its ASCO 2011 Online Summit featuring editorials and perspectives on new cancer therapeutic advances and changing treatment paradigms from scientific, clinical, patient advocacy and industry thought leaders. The Summit is specially designed to augment understanding and provide additional ...
- BioMarine International Business Convention Nantes-St-Nazaire, France September 7, 8 and 9, 2011 http ... Tuesday, May 17, 2011 @ 9:55AMReconciling economic requirements with the environmental constraints of the branch will be at the center of the concerns of the BioMarine International Business Convention 2011.
- Foreign envoys stress need for global cooperation Saturday, May 14, 2011 @ 12:42PMDehradun, May 14 : Envoys of 12 countries, who have converged in this hill capital to explore investment opportunities in various traditional as well as new avenues in Uttarakhand, today agreed that in the present scenario, vital issues, specially related to environment, had become borderless and enhanced global cooperation was the need of the hour.
- PolyMedix Presents Clinical and Pre-Clinical Data on PMX-30063 Defensin-Mimetic Antibiotic at ECCMID 2011 Meeting Thursday, May 12, 2011 @ 6:16AMRADNOR, Pa.--(BUSINESS WIRE)--PolyMedix, Inc. (OTC BB: PYMX), an emerging biotechnology company focused on developing new therapeutic drugs to treat life-threatening infectious diseases and acute cardiovascular disorders, presented new clinical and pre-clinical data related to the safety and efficacy of its novel, lead defensin-mimetic antibiotic, PMX-30063. PMX-30063 is currently being studied ...
- PolyMedix Announces Presentation of Four Abstracts at ECCMID 2011 Meeting Thursday, May 5, 2011 @ 6:15AMRADNOR, Pa.--(BUSINESS WIRE)--PolyMedix, Inc. (OTC BB: PYMX), an emerging biotechnology company focused on developing new therapeutic drugs to treat life-threatening infectious diseases and acute cardiovascular disorders, today announced the acceptance of four presentations on the Company’s lead antibiotic drug candidate, PMX-30063, at the European Congress of Clinical Microbiology and ...
- 2011 BIO International Convention To Host New Forum On Diabetes Wednesday, May 4, 2011 @ 7:31AMIn an effort to raise awareness for one of the most costly chronic diseases facing adults and children, the Biotechnology Industry Organization (BIO), together with the Juvenile Diabetes Research Foundation (JDRF), will feature a two-day diabetes forum for the first time at its 2011 BIO International Convention. The Convention will take place June 27-30, 2011, in Washington, D.C. at the Walter E ...
- PolyMedix Defensin-Mimetic Antibiotic PMX-30063 Active Against NDM-1 Drug-Resistant Bacteria Thursday, April 28, 2011 @ 6:08AMRADNOR, Pa.--(BUSINESS WIRE)--PolyMedix, Inc. (OTC BB: PYMX), a biotechnology company focused on developing new therapeutic drugs to treat patients with acute infectious diseases and cardiovascular disorders, announced today that its lead defensin-mimetic antibiotic, PMX-30063, has shown activity in an in vitro laboratory test against the NDM-1 drug resistant strain of Klebsiella pneumonia. NDM ...
- PolyMedix Defensin-Mimetic Antibiotics Show Activity in A Respiratory Infection Model Against Anthrax Tuesday, April 26, 2011 @ 6:13AMRADNOR, Pa.--(BUSINESS WIRE)--PolyMedix, Inc. (OTC BB: PYMX), a biotechnology company focused on developing new therapeutic drugs to treat patients with acute infectious diseases and cardiovascular disorders, announced today that several of its defensin-mimetic antibiotic compounds have shown antimicrobial efficacy in an animal model against the bacteria that causes anthrax. Anthrax is an acute ...
- Bill Cook, Indiana's richest man, dies at 80 Saturday, April 16, 2011 @ 9:07PMBill Cook donated millions to charitable organizations throughout the state, among them the new state headquarters for Indiana Landmarks in Indianapolis.
- Intnl. Biotechnology - Half Yearly Report Friday, April 15, 2011 @ 1:09AMIntnl. Biotechnology - Half Yearly Report
- RTP venture capital climate improved in Q1 but biotechs still clamor for cash Tuesday, April 12, 2011 @ 11:32PMEarly stage life science companies still developing their technologies can fall into a gap: too expensive to be supported by more grants or angel investments yet not far enough along to secure venture capital interest. In the worst economy in generations, their funding challenges are more pronounced. But the first quarter saw several companies in North [...]
- Mass. state agencies, local companies shoot to make a splash at BIO show Tuesday, April 12, 2011 @ 11:09PMMassachusetts state officials, industry groups, life sciences companies and educational institutions will have a dual purpose when they go to the BIO International Convention in Washington, D.C., in June. They will be promoting the 2012 version of BIO, which will be returning to Boston, where the show drew 23,000 attendees in 2007.
- Nuvilex, Inc. Announces Company Update Tuesday, April 12, 2011 @ 8:58AMSCOTTSDALE, Ariz.--(BUSINESS WIRE)--Nuvilex, Inc. (OTCQB: NVLX) is pleased to announce the new management team at Nuvilex has made significant inroads into strengthening the Company’s operations and footprint in nutritional supplements. Present activities include: We have formed a Marketing and Sales Department which has created a new, simplified environment for direct product sales, energized ...
- Nuvilex, Inc. Announces Company Update Tuesday, April 12, 2011 @ 8:47AMNuvilex, Inc. is pleased to announce the new management team at Nuvilex has made significant inroads into strengthening the Company’s operations and footprint in nutritional supplements.
- Under The Sea, Sex Is Slimy Business Thursday, April 7, 2011 @ 11:10AMIn Sex, Drugs, and Sea Slime: The Oceans' Oddest Creatures and Why They Matter , underwater researcher Ellen Prager describes some of the craziest activities that help ocean creatures stay alive, fight predators, find food and reproduce.
- VBL Therapeutics Presents Two Studies On VB-111 At 102nd Annual AACR Meeting Thursday, April 7, 2011 @ 8:38AMVBL Therapeutics, a clinical-stage biotechnology company committed to the development of novel treatments for immune-inflammatory diseases and cancer, announced preclinical data demonstrating VB-111's potential utility as a targeted cancer treatment. The company presented two studies, one demonstrating the safety and specificity of VB-111 and the other demonstrating its promise against ...
- VBL's VB-111 preclinical data against metastatic cancer presented at AACR meeting Wednesday, April 6, 2011 @ 11:53PMVBL Therapeutics, a clinical-stage biotechnology company committed to the development of novel treatments for immune-inflammatory diseases and cancer, today announced preclinical data demonstrating VB-111's potential utility as a targeted cancer treatment.
- VBL Therapeutics Presents Two Studies on VB-111 at 102nd Annual AACR Meeting Wednesday, April 6, 2011 @ 7:13AMTEL AVIV, Israel & ORLANDO, Fla.--(BUSINESS WIRE)--VBL Therapeutics, a clinical-stage biotechnology company committed to the development of novel treatments for immune-inflammatory diseases and cancer, today announced preclinical data demonstrating VB-111’s potential utility as a targeted cancer treatment. The company presented two studies, one demonstrating the safety and specificity of VB-111 ...
- Lawmakers haggle over stem cell funding Monday, April 4, 2011 @ 5:40PMLegislators again are at odds over funding for the state's stem cell research program — the nation's third-largest state-supported initiative behind California's and New York's.
- Cautionary Tales in Transmedia Storytelling Wednesday, March 30, 2011 @ 2:24PMIn her SXSW presentation on the ethics of transmedia storytelling, Andrea Phillips recounted a number of cautionary tales from the genre’s history in order to illuminate best practices in transmedia production.
- Notice of Annual General Meeting of Shareholders of Karo Bio Friday, March 25, 2011 @ 5:45AMHUDDINGE, Sweden--(BUSINESS WIRE)--Regulatory News: Karo Bio (STO:KARO) Right to participate A right to participate at the annual general meeting applies for those who have been recorded in the share register kept by Euroclear Sweden AB on April 19th, 2011, and who gives the Company notice of intent to participate at the annual general meeting no later than April 19th, 2011, at 4.00 pm CET ...
- Notice of Annual General Meeting of Shareholders of Karo Bio Friday, March 25, 2011 @ 5:42AMRegulatory News:
